Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00527761 · ClinicalTrials.gov registry record · Phase 1
Taxotere/Temodar/Cisplatin Study in Melanoma Patients
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00527761: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00527761 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00527761, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
Primary Objective: 1\. To determine the maximum tolerated dose of chemotherapy using Taxotere, Temodar, Cisplatin (TTC) in patients with metastatic melanoma. Secondary Objectives: 1. To determine the toxicity of chemotherapy using Taxotere, Temodar, Cisplatin (TTC) in patients with metastatic melanoma 2. To determine the response rate of induction chemotherapy using Taxotere, Temodar, Cisplatin (TTC) in patients with metastatic melanoma.
Interventions
- DRUG Docetaxel
- DRUG Cisplatin
- DRUG Temodar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2004-08 |
| Est. Completion | 2007-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00527761
The ClinicalTrials.gov registry entry for NCT00527761 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT00527761 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00527761 about?
NCT00527761 is a clinical study titled "Taxotere/Temodar/Cisplatin Study in Melanoma Patients". Primary Objective: 1\. To determine the maximum tolerated dose of chemotherapy using Taxotere, Temodar, Cisplatin (TTC) in patients with metastatic melanoma. Secondary Objectives: 1. To determine the toxicity of chemotherapy using Taxotere, Temodar, Cisplatin (TTC) in patients with metastatic mel...
What is the current status of trial NCT00527761?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2004-08. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00527761?
The interventions under investigation include: Docetaxel (DRUG), Cisplatin (DRUG), Temodar (DRUG).
Who is sponsoring clinical trial NCT00527761?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.